ArticleFrontiers in immunology2018
CD38 as Immunotherapeutic Target in Light Chain Amyloidosis and Multiple Myeloma-Association With Molecular Entities, Risk, Survival, and Mechanisms of Upfront Resistance.
Article in Frontiers in immunology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 44 citations in OpenAlex.
- Trial
- Prospective target assessment and multimodal prediction of survival for personalized and risk-adapted treatment strategies in multiple myeloma in the GMMG-MM5 multicenter trial.Journal of hematology & oncology · 2019Trial
- Efficacy and Safety of Low-Frequency Daratumumab Regimen in Systemic Light-Chain Amyloidosis.Cancer medicine · 2026Article
- Ablation of CD38 in multiple myeloma cells leads to an aggressive phenotype in a mouse xenograft model.Blood advances · 2026Article
- Bortezomib-releasing silica-collagen xerogels for local treatment of osteolytic bone- and minimal residual disease in multiple myeloma.Journal of hematology & oncology · 2024Article
- Cell surface marker heterogeneity in human myeloma cell lines for modeling of disease and therapy.Scientific reports · 2024Article
- Quantitative Integrative Survival Prediction in Multiple Myeloma Patients Treated With Bortezomib-Based Induction, High-Dose Therapy and Autologous Stem Cell Transplantation.JCO precision oncology · 2024Article
- Review
- Daratumumab Treatment for "Truly Frail" Elderly Myeloma Patients.Life (Basel, Switzerland) · 2024Review
- Identification of NOTCH-driven matrisome-associated genes as prognostic indicators of multiple myeloma patient survival.Blood cancer journal · 2023Article
- Safety and Efficacy of Subcutaneous Daratumumab in Systemic AL Amyloidosis.Therapeutics and clinical risk management · 2023Review
- RNA-sequencing based first choice of treatment and determination of risk in multiple myeloma.Frontiers in immunology · 2023Article
- Efficacy and safety of intravenous daratumumab-based treatments for AL amyloidosis: a systematic review and meta-analysis.Cancer cell international · 2022Review
- MCT1 is a predictive marker for lenalidomide maintenance therapy in multiple myeloma.Blood advances · 2022Article
- Molecular Mechanisms of Cardiac Amyloidosis.International journal of molecular sciences · 2021Review
- From Descriptive to Functional Genomics of Leukemias Focusing on Genome Engineering Techniques.International journal of molecular sciences · 2021Review
- Bone Marrow Microenvironment Interplay and Current Clinical Practice in Multiple Myeloma: A Review of the Balkan Myeloma Study Group.Journal of clinical medicine · 2021Review
- Genetic pathogenesis of immunoglobulin light chain amyloidosis: basic characteristics and clinical applications.Experimental hematology & oncology · 2021Review
- Review
- Treatment Strategies Considering Micro-Environment and Clonal Evolution in Multiple Myeloma.Cancers · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Monoclonal antibodies against the cell surface antigen CD38, e.g., isatuximab, daratumumab, or Mor202, have entered the therapeutic armamentarium in multiple myeloma due to single agent overall response rates of 29 vs. 36 vs. 31%, effectivity in combination regimen, e.g., with lenalidomide or bortezomib plus dexamethasone, and tolerable side effects. Despite clinical use, many questions remain. In this manuscript, we address three of these: first, upfront CD38 target-expression in AL-amyloidosis, monoclonal gammopathy of unknown significance (MGUS), asymptomatic, symptomatic, and relapsed multiple myeloma. Second, relation of CD38-expression to survival, disease stages, molecular entities, and high-risk definitions. Third, alternative splicing or lack of CD38-expression as potential mechanisms of upfront resistance. We assessed CD138-purified plasma cell samples from 196 AL-amyloidosis, 62 MGUS, 259 asymptomatic, 764 symptomatic, and 90 relapsed myeloma patients, including longitudinal pairs of asymptomatic/symptomatic (
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.